Exact Sciences stock exits Nasdaq after Abbott deal

Published on 10/07/2026 at 07:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Abbott completed its Exact Sciences acquisition for USD 105.00 per share on March 23, 2026. Exact Sciences reported USD 3.25 billion in 2025 revenue, up 18 percent.

Aquarellgemälde der Skyline von Madison Wisconsin, Heimatstadt von Exact Sciences Corp — Exact Sciences Corp. hat seinen Hauptsitz in der Universitätsstadt Madison im US-Bundesstaat Wisconsin US30063P1057, Illustration mit AI erstellt.

Exact Sciences stock (ISIN US30063P1057) exited Nasdaq after Abbott completed its acquisition on March 23, 2026, with each share converted into USD 105.00 in cash, according to Ticker Scout. The transaction changed the company from a listed cancer-diagnostics specialist into a wholly owned Abbott subsidiary.

Abbott deal ends public listing

The merger made Exact Sciences part of Abbott's Cancer Diagnostics business, bringing Cologuard, Oncotype DX and Cancerguard into the larger healthcare group. The cash consideration valued the equity at USD 105.00 per share, while Abbott's filing summary put the total transaction value at USD 20.6 billion, according to Ticker Scout.

Exact Sciences shares last traded on Nasdaq on March 20, 2026, before the acquisition became effective three days later, according to Edgechat. That date is the relevant market checkpoint for investors researching the former EXAS ticker.

Revenue reached USD 3.25 billion

In fiscal year 2025, Exact Sciences generated USD 3.25 billion in revenue, an 18 percent increase from the prior year, according to Edgechat. Screening contributed USD 2.53 billion, while precision oncology generated USD 717 million.

The revenue mix explains Abbott's strategic rationale. Screening accounted for 77.8 percent of the USD 3.25 billion total, while precision oncology represented 22.1 percent, based on the reported segment figures. Exact Sciences also delivered more than 5.5 million results to patients across its cancer-testing portfolio in 2025, according to Edgechat.

Abbott carries the growth story

For investors, the central shift is ownership rather than a new trading signal: the Exact Sciences business now contributes to Abbott's diagnostics results instead of publishing standalone public-company results. Abbott's latest filing summary says the acquired business contributed USD 1.0 billion of sales in the first six months of 2026, according to Ticker Scout.

Exact Sciences stock therefore represents a completed acquisition case, with USD 105.00 per share as the final cash consideration and March 20, 2026 as the final Nasdaq trading date.